Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HPN424 |
| Synonyms | |
| Therapy Description |
HPN424 is an antibody that binds to PSMA and CD3 on T-cells, potentially resulting in increased immune response against PSMA-expressing tumor cells (Cancer Res July 1 2018 (78) (13 Supplement) 1773). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HPN424 | HPN-424|HPN 424 | CD3 Antibody 120 PSMA Antibody 23 | HPN424 is an antibody that binds to PSMA and CD3 on T-cells, potentially resulting in increased immune response against PSMA-expressing tumor cells (Cancer Res July 1 2018 (78) (13 Supplement) 1773). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03577028 | Phase I | HPN424 | Study of HPN424 in Patients With Advanced Prostate Cancer | Terminated | USA | GBR | 0 |